ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.
Opening soon Phase 1 NCT07680673
Run by Encellin · for 18 to 75 · All sexes
What this study is about
This study will evaluate the safety and performance of ENCRT-103-hPI, which is a cargo of primary islets inside Encellin's ENC-103-CED. The 103 offers a soft pillow-like encasing to contain and protect the cells from the immune system. The product is implanted in the upper arm or abdomen and is approximately the size of a quarter. Eligibility is open to both patients on a standard of care islet infusion wait list, as well as those who are not. Participation in this trial does not preclude future Encellin trial participation. The study duration is 4.5months and requires keeping the implant for 4 months, as well as adhering to a standard of care schedule of follow ups during the implant period.
Who can join (things the study team will check)
✅ You may be able to join if…
- follows those of the institutions' standard of care (cohort A) or care team's guidelines (cohort B).
🚫 You may not be able to join if…
- - follows those of the institutions' standard of care (cohort A) or care team's guidelines (cohort B).
Where this trial is running
- Vancouver General Hospital, Vancouver, British Columbia, Canada
- UHN, Toronto, Ontario, Canada
- McGill University Health Centre, Montreal, Quebec, Canada
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.